# E-cigarette use, measured for the first time, emerged as a major concern at 17 percent, indicating a clear shift from ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Why did Health Secretary Wes Streeting say Britain was going to be a fat-free country within a decade when it's a promise he ...

A new study found that Ozempic's main ingredient may treat people with type 1 diabetes, control blood sugar, and lose weight.

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...